Cerebral Palsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cerebral palsy markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 2.53% during 2024-2034.
The cerebral palsy market has been comprehensively analyzed in IMARC's new report titled "Cerebral Palsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cerebral palsy refers to a group of neurological conditions that affect body’s movement and posture. The symptoms of the ailment vary widely from person to person and may include poor muscle control as well as coordination, abnormal muscle tone, spasticity (stiffness of the muscles), ataxia (incoordination and lack of balance), tremors or involuntary movements, difficulty with speech and communication, vision or hearing problems, cognitive impairments, etc. The severity of the indications can range from mild to severe and may affect different parts of the body, such as the arms, legs, face, etc. Diagnosing the ailment typically involves a comprehensive investigation by a team of healthcare professionals, including a neurologist, developmental pediatrician, physical therapist, etc. The evaluation consists of a review of medical history and symptoms, a physical examination, and various diagnostic tests, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, genetic testing, electromyography (EMG), movement analysis, etc. Various standardized assessments, including the Gross Motor Function Classification System (GMFCS) and the Manual Ability Classification System (MACS), are also used to evaluate motor function and level of disability in children with cerebral palsy.
The increasing cases of prenatal, perinatal, and postnatal brain damage are primarily driving the cerebral palsy market. Additionally, the rising prevalence of maternal health factors, such as infections, high blood pressure, gestational diabetes, etc., which can increase the risk of cerebral palsy in the child, is also creating a positive outlook for the market. Moreover, the escalating utilization of several medications, including baclofen, botulinum toxin injections, anticonvulsants, etc., to treat specific symptoms, such as muscle spasticity and seizures, is further augmenting the market growth. Besides this, the widespread adoption of selective dorsal rhizotomy, in which the sensory nerve roots in the spinal cord are selectively cut to reduce spasticity and improve mobility, as a treatment option is also propelling the market growth. Furthermore, various key players are making extensive investments in developing novel diagnostic devices that can aid in identifying anatomical abnormalities in the brain associated with cerebral palsy. This, in turn, is acting as another significant growth-inducing factor. Additionally, the introduction of assistive technology, such as mobility aids, communication devices, adaptive equipment, etc., that help patients to improve their quality of life is expected to drive the cerebral palsy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the cerebral palsy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cerebral palsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cerebral palsy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cerebral palsy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cerebral palsy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cerebral palsy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cerebral palsy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cerebral palsy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cerebral palsy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cerebral palsy across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral palsy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral palsy by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral palsy by type across the seven major markets?
How many patients are diagnosed (2018-2034) with cerebral palsy across the seven major markets?
What is the size of the cerebral palsy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cerebral palsy?
What will be the growth rate of patients across the seven major markets?
Cerebral Palsy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cerebral palsy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cerebral palsy market?
What are the key regulatory events related to the cerebral palsy market?
What is the structure of clinical trial landscape by status related to the cerebral palsy market?
What is the structure of clinical trial landscape by phase related to the cerebral palsy market?
What is the structure of clinical trial landscape by route of administration related to the cerebral palsy market?
The cerebral palsy market has been comprehensively analyzed in IMARC's new report titled "Cerebral Palsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cerebral palsy refers to a group of neurological conditions that affect body’s movement and posture. The symptoms of the ailment vary widely from person to person and may include poor muscle control as well as coordination, abnormal muscle tone, spasticity (stiffness of the muscles), ataxia (incoordination and lack of balance), tremors or involuntary movements, difficulty with speech and communication, vision or hearing problems, cognitive impairments, etc. The severity of the indications can range from mild to severe and may affect different parts of the body, such as the arms, legs, face, etc. Diagnosing the ailment typically involves a comprehensive investigation by a team of healthcare professionals, including a neurologist, developmental pediatrician, physical therapist, etc. The evaluation consists of a review of medical history and symptoms, a physical examination, and various diagnostic tests, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, genetic testing, electromyography (EMG), movement analysis, etc. Various standardized assessments, including the Gross Motor Function Classification System (GMFCS) and the Manual Ability Classification System (MACS), are also used to evaluate motor function and level of disability in children with cerebral palsy.
The increasing cases of prenatal, perinatal, and postnatal brain damage are primarily driving the cerebral palsy market. Additionally, the rising prevalence of maternal health factors, such as infections, high blood pressure, gestational diabetes, etc., which can increase the risk of cerebral palsy in the child, is also creating a positive outlook for the market. Moreover, the escalating utilization of several medications, including baclofen, botulinum toxin injections, anticonvulsants, etc., to treat specific symptoms, such as muscle spasticity and seizures, is further augmenting the market growth. Besides this, the widespread adoption of selective dorsal rhizotomy, in which the sensory nerve roots in the spinal cord are selectively cut to reduce spasticity and improve mobility, as a treatment option is also propelling the market growth. Furthermore, various key players are making extensive investments in developing novel diagnostic devices that can aid in identifying anatomical abnormalities in the brain associated with cerebral palsy. This, in turn, is acting as another significant growth-inducing factor. Additionally, the introduction of assistive technology, such as mobility aids, communication devices, adaptive equipment, etc., that help patients to improve their quality of life is expected to drive the cerebral palsy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the cerebral palsy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cerebral palsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cerebral palsy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cerebral palsy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cerebral palsy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cerebral palsy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cerebral palsy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cerebral palsy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cerebral palsy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cerebral palsy across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral palsy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral palsy by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of cerebral palsy by type across the seven major markets?
How many patients are diagnosed (2018-2034) with cerebral palsy across the seven major markets?
What is the size of the cerebral palsy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cerebral palsy?
What will be the growth rate of patients across the seven major markets?
Cerebral Palsy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cerebral palsy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cerebral palsy market?
What are the key regulatory events related to the cerebral palsy market?
What is the structure of clinical trial landscape by status related to the cerebral palsy market?
What is the structure of clinical trial landscape by phase related to the cerebral palsy market?
What is the structure of clinical trial landscape by route of administration related to the cerebral palsy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CEREBRAL PALSY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CEREBRAL PALSY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CEREBRAL PALSY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 CEREBRAL PALSY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CEREBRAL PALSY - UNMET NEEDS
10 CEREBRAL PALSY - KEY ENDPOINTS OF TREATMENT
11 CEREBRAL PALSY - MARKETED PRODUCTS
11.1 List of Cerebral Palsy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CEREBRAL PALSY - PIPELINE DRUGS
12.1 List of Cerebral Palsy Pipeline Drugs Across the Top 7 Markets
12.1.1 UDI-001 - Rohto Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Botulinum toxin type A - Hugel
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Valbenazine - Neurocrine Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Epoetin alfa biosimilar - LG Chem
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 AlloRx- Vitro Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CEREBRAL PALSY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CEREBRAL PALSY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CEREBRAL PALSY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cerebral Palsy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cerebral Palsy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cerebral Palsy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cerebral Palsy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cerebral Palsy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cerebral Palsy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cerebral Palsy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cerebral Palsy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cerebral Palsy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cerebral Palsy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cerebral Palsy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cerebral Palsy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cerebral Palsy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cerebral Palsy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cerebral Palsy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cerebral Palsy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cerebral Palsy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cerebral Palsy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cerebral Palsy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cerebral Palsy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cerebral Palsy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cerebral Palsy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cerebral Palsy - Access and Reimbursement Overview
16 CEREBRAL PALSY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CEREBRAL PALSY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CEREBRAL PALSY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CEREBRAL PALSY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CEREBRAL PALSY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CEREBRAL PALSY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 CEREBRAL PALSY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CEREBRAL PALSY - UNMET NEEDS
10 CEREBRAL PALSY - KEY ENDPOINTS OF TREATMENT
11 CEREBRAL PALSY - MARKETED PRODUCTS
11.1 List of Cerebral Palsy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CEREBRAL PALSY - PIPELINE DRUGS
12.1 List of Cerebral Palsy Pipeline Drugs Across the Top 7 Markets
12.1.1 UDI-001 - Rohto Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Botulinum toxin type A - Hugel
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Valbenazine - Neurocrine Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Epoetin alfa biosimilar - LG Chem
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 AlloRx- Vitro Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CEREBRAL PALSY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CEREBRAL PALSY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CEREBRAL PALSY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cerebral Palsy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cerebral Palsy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cerebral Palsy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cerebral Palsy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cerebral Palsy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cerebral Palsy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cerebral Palsy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cerebral Palsy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cerebral Palsy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cerebral Palsy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cerebral Palsy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cerebral Palsy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cerebral Palsy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cerebral Palsy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cerebral Palsy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cerebral Palsy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cerebral Palsy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cerebral Palsy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cerebral Palsy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cerebral Palsy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cerebral Palsy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cerebral Palsy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cerebral Palsy - Access and Reimbursement Overview
16 CEREBRAL PALSY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CEREBRAL PALSY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CEREBRAL PALSY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
